CRIS Current Research Information System

STEFONI, VITTORIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.634
EU - Europa 3.454
AS - Asia 1.498
AF - Africa 256
SA - Sud America 15
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 9.866
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.606
GB - Regno Unito 827
SE - Svezia 771
VN - Vietnam 641
IT - Italia 569
DE - Germania 456
CN - Cina 442
IN - India 187
IE - Irlanda 167
UA - Ucraina 159
FR - Francia 130
RU - Federazione Russa 112
TG - Togo 93
SG - Singapore 89
JO - Giordania 59
ZA - Sudafrica 58
EE - Estonia 57
CI - Costa d'Avorio 56
HR - Croazia 49
NG - Nigeria 40
BE - Belgio 29
CH - Svizzera 29
CA - Canada 25
FI - Finlandia 24
IR - Iran 21
PL - Polonia 19
BG - Bulgaria 15
JP - Giappone 15
ES - Italia 13
HK - Hong Kong 13
BR - Brasile 9
SC - Seychelles 9
LB - Libano 7
AT - Austria 6
NL - Olanda 6
RO - Romania 6
MY - Malesia 5
TR - Turchia 5
UZ - Uzbekistan 5
AU - Australia 3
IL - Israele 3
MX - Messico 3
NZ - Nuova Zelanda 3
PE - Perù 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BN - Brunei Darussalam 2
CL - Cile 2
CZ - Repubblica Ceca 2
GR - Grecia 2
NO - Norvegia 2
BY - Bielorussia 1
DK - Danimarca 1
EC - Ecuador 1
EU - Europa 1
HU - Ungheria 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
OM - Oman 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 9.866
Salva come PNG Salva come JPEG
Città #
Southend 744
Fairfield 624
Chandler 508
Ashburn 369
Houston 321
Woodbridge 314
Seattle 272
Ann Arbor 269
Wilmington 256
Dong Ket 255
Cambridge 220
Princeton 206
Dublin 167
Jacksonville 99
Lomé 93
Berlin 84
Bologna 83
Westminster 78
Nanjing 76
New York 68
Padova 64
Singapore 62
Amman 59
Abidjan 56
Bremen 53
Turin 50
Jinan 47
Beijing 43
Shenyang 41
Abeokuta 39
Boardman 36
Milan 36
San Diego 35
Saint Petersburg 31
Los Angeles 29
Redwood City 29
Jiaxing 28
Changsha 26
Rome 26
Brussels 25
Florence 25
Nanchang 25
Dearborn 24
Helsinki 24
Hebei 22
Bern 21
Des Moines 20
Falls Church 19
Hyderabad 19
Hangzhou 16
Redmond 16
Tianjin 16
Toronto 16
Zhengzhou 16
Mülheim 15
Warsaw 14
Olalla 13
Tokyo 13
Sofia 12
Taizhou 11
Zanjan 11
Catania 10
Norwalk 9
Bühl 8
Mahé 8
Modena 8
Monmouth Junction 8
Paris 8
Rijeka 8
Taiyuan 8
Wayne 8
Hong Kong 7
London 7
San Francisco 7
Andover 6
Haikou 6
Medford 6
Ningbo 6
São Paulo 6
Verona 6
Vienna 6
Buffalo 5
Dallas 5
Falconara Marittima 5
Frankfurt am Main 5
Kunming 5
Parma 5
Phoenix 5
Reggio Emilia 5
Fremont 4
Gallarate 4
Genoa 4
Guangzhou 4
Hefei 4
Kuala Lumpur 4
Lanzhou 4
Leawood 4
Madrid 4
Mountain View 4
Nivelles 4
Totale 6.519
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 194
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 187
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 174
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 171
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 168
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 166
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 166
18 F-FDG PET in malignant lymphoma: significance of positive findings 160
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 159
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 153
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 146
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 145
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 145
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 143
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 143
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 142
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 141
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 141
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 138
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 134
Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. 134
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 133
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 132
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 126
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 122
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 121
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial 121
CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. 120
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis 119
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 118
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 118
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 117
Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. 115
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 113
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia 113
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS 112
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 111
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 111
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 110
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 109
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 109
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 109
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 108
Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. 106
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 105
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 105
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 104
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. 104
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. 104
Discordant response to chemotherapy: An unusual patternof fluoro-deoxy-d-glucose uptake in heavily pre-treated lymphoma patients. 103
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 103
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. 103
Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. 102
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 102
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 101
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 100
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 100
Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. 99
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 98
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 98
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 96
Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. 94
FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma. 90
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 90
Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience 90
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). 89
Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. 89
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 86
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial 84
Chronic lymphocytic leukemia focus in the context of a cardiac mass in a pretreated patient: an exceptional incidental finding 83
Rituximab in primary conjunctiva lymphoma. 82
Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine 81
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. 80
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. 79
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 78
FDG-PET in the serial assessment of patinets with lymphoma in complete remission 77
Role of autologous stem cell transplantation in T-cell lymphoma patients: a single institution retrospective analysis 76
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 73
Clinical significance of axillary findings in patients with lymphoma during follow up. C 71
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 71
null 63
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 62
Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience 60
Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma 57
First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi 55
Finalization of autologous stem cell transplant in complex and multirelapsed follicular lymphoma 50
Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience 47
Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series 43
Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience 42
Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience. 39
A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy 39
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 36
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 30
Intravascular Large B-cell Lymphoma Successfully Treated with Autologous Transplantation 30
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study 29
Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T-cell lymphoma: A FIL phase 2 study 29
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 26
Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases 25
Hepatosplenic T-cell non-Hodgkin lymphoma cured with tandem autologous and allogeneic stem cell transplantation 23
Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. 22
Totale 10.020
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.792
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.792
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.186 0 60 20 149 268 278 306 335 357 175 111 127
2020/20211.617 248 96 44 52 46 131 11 81 159 61 92 596
2021/20222.113 310 54 132 258 149 98 37 133 61 145 425 311
2022/20232.366 246 346 159 300 177 185 52 140 413 68 159 121
2023/2024744 62 112 57 93 59 106 48 44 26 53 33 51
2024/2025158 136 22 0 0 0 0 0 0 0 0 0 0
Totale 10.145